Experience in Growth Hormone Therapy in Noonan Syndrome in Japan
スポンサーリンク
概要
- 論文の詳細を見る
Thirty-nine children with Noonan syndrome were treated with growth hormone (GH). Prepubertal height velocity was 4.25 ± 1.31 cm/year (M ± SD) (n=38) before GH therapy, which was increased to 6.23 ± 0.87 cm/year (n=33) in the first year, to 4.92 ± 1.15 cm/year (n=22) in the second year and 4.76 ± 1.25 cm/year (n=13) in the third year. Height velocity SDS for chronological age and height velocity (SDS) for bone age were also improved in the 1st year, but declined progressively during the subsequent years. No adverse effects were observed during GH treatment.<BR>These data indicate that GH may be effective in Noonan syndrome, but further studies are required to evaluate the efficacy of long-term GH therapy on adult height and body proportions.
- 日本小児内分泌学会の論文
日本小児内分泌学会 | 論文
- 43 Common origin of the Q258X mutation in StAR gene responsible for congenital aderenal lipoid hyperplasia in Japanese
- Recent Change in the Annual Incidence of Childhood Type 2 Diabetes in the Tokyo Metropolitan Area
- A Case of Acute Lymphoblastic Leukemia with Prader-Willi Syndrome during Growth Hormone Therapy
- Characteristics of a Fulminant Onset Form of Idiopathic Type 1 Diabetes Mellitus in Japanese Children
- Different Skeletal Phenotypes in a Mother and Two Daughters with Short Stature Homeobox-Containing Haploinsufficiency